Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People diagnosed with non-small cell lung cancer (a specific type of lung cancer) at a mid-to-advanced stage (clinical stage II to IIIB).
- People whose lung cancer does not have specific gene changes known as EGFR or ALK mutations.
- People aged 18 years or older.
- People who are planned to receive immunotherapy treatment before surgery.
- People with a good general level of physical fitness and ability to carry out daily activities, as rated by a standard medical scale (ECOG score of 0 or 1) (confirm with trial site).
- People with a life expectancy of at least 12 weeks.
- People who are able to understand and sign a written consent form.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have another type of cancer in addition to their lung cancer (exceptions may apply for certain skin cancers or cancers that were fully treated more than 5 years ago with no return of the disease).
- People who have previously received chemotherapy, radiotherapy, or any other systemic anti-cancer treatment.
- People who have an autoimmune disease that would make treatment with a type of immunotherapy drug (PD-1 monoclonal antibody) unsuitable — this includes conditions such as myasthenia gravis, myositis, lupus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and several other autoimmune conditions.
- People who are considered unlikely to follow the trial's requirements, such as those who may be unable to attend follow-up visits or complete the study, as assessed by the trial doctor.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 15216769608
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
Pathological response after immune neoadjuvant therapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.